DM
Therapeutic Areas
Mayne Pharma Group Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nextstellis (drospirenone/estetrol) | Oral Contraception / Hormone Therapy | Approved |
| Lidocaine Topical System 1.8% | Postherpetic Neuralgia (PHN) | Approved |
| Fabior (tazarotene) Foam | Acne Vulgaris | Approved |
| Sorilux (calcipotriene) Foam | Plaque Psoriasis | Approved |
| Doryx (doxycycline hyclate) MPC | Severe Acne | Approved |
| Pipeline of Complex Generics | Various | Development |
| Pipeline of 505(b)(2) Products | Various (Women's Health, Dermatology) | Pre-clinical to Phase 3 |
Leadership Team at Mayne Pharma Group
SR
Scott Richards
Non-Executive Chairman
SL
Shaun Larkin
Managing Director & Chief Executive Officer
DC
David Cowley
Chief Financial Officer
M(
Michael (Mick) O'Brien
Chief Commercial Officer, US Generics
DJ
Dr. James (Jim) Hall
President, Mayne Pharma International & President, Mayne Pharma USA (Branded)
BM
Brent Matthews
Chief Operating Officer
DM
Dr. Michelle Miller
Chief Scientific Officer (Development)
KC
Karen Cohen
Company Secretary & General Counsel
P(
Phillipa (Pippa) Leary
Non-Executive Director
J(
John (Rob) Kelly
Non-Executive Director